-
Publication
A peer reviewed publication.
Citation
Citation information for the publication itself.
A. Camara, M. S. Sow, A. Toure, O. H. Diallo, I. Kaba, B. Bah, T. H. Diallo, et al. "[Treatment Outcome, Survival and Their Risk Factors among New Tuberculosis Patients Co-Infected with Hiv During the Ebola Outbreak in Conakry]." Rev Epidemiol Sante Publique 65, no. 6 (Nov 2017): 419-26.
Abstract
<div class="Abstracts">
<div class="abstract author">
<h2 class="section-title">Résumé</h2>
<div>
<h3>Objectif</h3>
<p>La mortalité chez les patients tuberculeux co-infectés par le virus de l’immunodéficience humaine (VIH) est encore élevée en Afrique. Cette étude visait à estimer la survie et ses facteurs de risque dans une cohorte de patients tuberculeux co-infectés par le VIH qui a commencé un traitement antituberculeux durant l’épidémie d’Ebola à Conakry, en Guinée.</p>
</div>
<div>
<h3>Méthodes</h3>
<p>Une étude de cohorte prospective a été menée entre avril 2014 et décembre 2015, chez les nouveaux tuberculeux co-infectés par le VIH durant le traitement antituberculeux dans le CHU de Conakry. Les données de survie ont été analysées avec le logiciel SPSS 21.0. La méthode de Kaplan–Meier, le test du log-rank et le modèle de Cox ont été utilisés pour analyser les facteurs de risque du décès.</p>
</div>
<div>
<h3>Résultats</h3>
<p>Sur les 573 tuberculeux co-infectés par le VIH étudiés, 86 (15,0 %) étaient décédés avant la fin du traitement antituberculeux avec 52 % des décès survenus dans les huit semaines suivant le début de traitement. La survie à 4, 12 et 24 semaines après le début du traitement de la tuberculose était de 92 %, 86 % et 83 % respectivement. Les facteurs indépendamment associés au décès chez les patients tuberculeux co-infectés par le VIH étaient, le taux de cellule CD4 < 200 cellules/mm<sup>3</sup> (ratio du risque ajusté [RRA] : 2,25 ; IC95 % 1,16 à 4,37), avoir plus d’une infection opportuniste en plus de la tuberculose (RRA : 2,89 ; IC95 % 1,39 à 6,02) et avoir des comorbidités (RRA : 4,12 ; IC95 % 2,10 à 8,10). Une augmentation d’une unité du taux d’hémoglobine (RRA : 0,81 ; IC95 % 0,75 à 0,91) préservait du décès.</p>
</div>
<div>
<h3>Conclusion</h3>
<p>Les patients tuberculeux co-infectés par le VIH avaient un taux de létalité élevé pendant le traitement de la tuberculose. La prévention des infections opportunistes, de l’anémie et la prise en charge adéquate des comorbidités en début de traitement antituberculeux peuvent améliorer la survie de ces patients tuberculeux co-infectés par le VIH en rétablissant la fonction immunitaire.</p>
</div>
</div>
<div class="abstract author">
<h2 class="section-title">Abstract</h2>
<div>
<h3>Background</h3>
<p>Mortality among TB/HIV co-infected patients remains high in Africa. The study aimed to estimate survival and associated factors in a cohort of TB/HIV co-infected patients who started tuberculosis treatment during the Ebola outbreak in Conakry, Guinea.</p>
</div>
<div>
<h3>Methods</h3>
<p>A prospective cohort study was conducted from April 2014 to December 2015. TB patients with HIV co-infection were enrolled at the University Hospital of Conakry. Survival and risk factors were analyzed according to Kaplan–Meier's method, log-rank test and Cox's regression.</p>
</div>
<div>
<h3>Results</h3>
<p>Data from 573 patients were analyzed. From these, 86 (15.0%) died before the end of treatment, 52% occurring within eight weeks of treatment onset. Survival at 4, 12 and 24 weeks after the beginning of the TB treatment was 92%, 86% and 83%, respectively. Independent risk factors associated with death were in the cell CD4 < 200 cells/mm<sup>3</sup> [adjusted hazard ratio (AHR): 2.25; 95% CI (confidence intervals): 1.16–4.37], opportunistic infections other than TB [AHR: 2.89; 95% CI: 1.39–6.02], and comorbidities [AHR: 4.12; 95% CI: 2.10–8.10]. An increase of one unit in hemoglobin [AHR: 0.81; 95% CI: 0.75–0.91] was protective of death.</p>
</div>
<div>
<h3>Conclusion</h3>
<p>TB/HIV co-infected patients had a higher fatality rate during treatment of tuberculosis. Prevention of opportunistic infections, anemia and proper management of tuberculosis treatment in early comorbidities may improve survival for TB/HIV co-infected patients in restoring immune function.</p>
</div>
</div>
</div>
Accessibility
Information on accessibility of the document(s), such as university log-in necessary, request form, open access, etc.
pay online, or with Elsevier subscription
URL
https://www.ncbi.nlm.nih.gov/pubmed/29066256
Read Online
Online location of the resource.
https://www.sciencedirect.com/science/article/pii/S0398762017304935?via%3Dihub
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Treatment outcome, survival and their risk factors among new tuberculosis patients co-infected with HIV during the Ebola outbreak in Conakry/L’issue du traitement, la survie et ses facteurs de risque chez les nouveaux tuberculeux co-infectés par le VIH pendant l’épidémie d’Ebola à Conakry
Subject
The topic of the resource
Contenu Français
Description
An account of the resource
Mortality among TB/HIV co-infected patients remains high in Africa. The study aimed to estimate survival and associated factors in a cohort of TB/HIV co-infected patients who started tuberculosis treatment during the Ebola outbreak in Conakry, Guinea.
Creator
An entity primarily responsible for making the resource
Camara A, Sow MS, Touré A, Diallo OH, Kaba I, Bah B, Diallo TH, Diallo MS, Guilavogui T, Sow OY.
Date
A point or period of time associated with an event in the lifecycle of the resource
2017-11-01
Type
The nature or genre of the resource
Publication
Co-infection
Ebola
Français
French
R-Res&Pub
Survivors
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Discover
Description
An account of the resource
<div style="background-color:#c7e5f8;">
<h2 style="background-color:#c7e5f8;"><span style="font-size:80%;line-height:24px;"><a href="https://repository.netecweb.org/exhibits/show/ncov/ncov"><button>COVID-19 Update</button></a><a href="https://repository.netecweb.org/news#Map"><button>Outbreak Map</button></a><a href="https://repository.netecweb.org/news#News"><button>Newsfeed</button></a><a href="https://repository.netecweb.org/exhibits/show/monkeypox/monkeypox"><button>Monkeypox 2021</button></a><a href="https://repository.netecweb.org/exhibits/show/drcebola2018/drcebola2018"><button>2020 Ebola Update</button></a><a href="https://repository.netecweb.org/ebolatimeline"><button>Ebola Timeline</button></a><a href="https://repository.netecweb.org/exhibits/show/mers/mers"><button>MERS</button></a><a href="https://repository.netecweb.org/exhibits/show/aerosol/aerosol"><button>Airborne Transmission</button></a></span></h2>
<h2 style="background-color:#c7e5f8;">Discover Background Data and Resources:</h2>
<ul><li>
<p><span style="line-height:24px;">Get introduced to NETEC through the interactive timeline of special pathogens below.* This timeline describes some significant special pathogen events in recent history.</span></p>
</li>
<li>
<p><span style="line-height:24px;">Find out more about the 2014 Ebola outbreak and the development of the ASPR/CDC-supported network of healthcare facilities preparing for the next outbreak through <em><a href="/ebolatimeline"><button>the Ebola timeline</button></a>.</em></span></p>
</li>
</ul><ul><li>
<p><span style="line-height:24px;">This NETEC Repository helps to provide training and educational resources to prepare for future special pathogen events. </span></p>
</li>
</ul><ul><li>
<p><span style="line-height:24px;">Explore the files BELOW THE TIMELINE to <em><strong>discover and learn</strong></em> more about Ebola and other Special Pathogens, an overview of special pathogens, clinically managing patients affected, and readying healthcare teams and systems to keep everyone safe.</span></p>
</li>
</ul><h2 style="background-color:#c7e5f8;">Timeline of Special Pathogens:</h2>
<a href="#click">Skip timeline</a>
<p style="margin-bottom:0;"><iframe width="100%" height="635" style="border:1px solid #000000;" src="https://cdn.knightlab.com/libs/timeline3/latest/embed/index.html?source=1AQiHJEzkhEi71uIi7wTWWgSFRwR6wRbRyfhbASrw3Ig&font=Default&lang=en&initial_zoom=2&height=650" title="Timeline of Special Pathogens"></iframe></p>
<h2 style="background-color:#c7e5f8;"><span style="font-size:70%;">*Click for <a href="/timeline2access"><button>a screen reader accessible table of this timeline</button></a>. </span></h2>
</div>
Publication
A peer reviewed publication.
Citation
Citation information for the publication itself.
Khanna, S., and C. S. Kraft. 2021. "The interplay of SARS-CoV-2 and Clostridioides difficile infection." Future Microbiol 16:439-43.
Abstract
<div class="abstract-content selected">
<p>The COVID-19 pandemic has changed the way we practice medicine and lead our lives. In addition to pulmonary symptoms; COVID-19 as a syndrome has multisystemic involvement including frequent gastrointestinal symptoms such as diarrhea. Due to microbiome alterations with COVID-19 and frequent antibiotic exposure, COVID-19 can be complicated by <i>Clostridioides difficile</i> infection. Co-infection with these two can be associated with a high risk of complications. Infection control measures in hospitals is enhanced due to the COVID-19 pandemic which in turn appears to reduce the incidence of hospital-acquired infections such as <i>C. difficile</i> infection. Another implication of COVID-19 and its potential transmissibility by stool is microbiome-based therapies. Potential stool donors should be screened COVID-19 symptoms and be tested for COVID-19.</p>
</div>
<p><strong class="sub-title"> Keywords: </strong> COVID-19; Clostridioides difficile; colitis; diarrhea; infection; pandemic.</p>
Accessibility
Information on accessibility of the document(s), such as university log-in necessary, request form, open access, etc.
Free access on Future Medicine.
URL
https://pubmed.ncbi.nlm.nih.gov/33847139/
Read Online
Online location of the resource.
https://www.futuremedicine.com/doi/full/10.2217/fmb-2020-0275
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The interplay of SARS-CoV-2 and Clostridioides difficile infection
Subject
The topic of the resource
Research
Description
An account of the resource
The COVID-19 pandemic has changed the way we practice medicine and lead our lives. In addition to pulmonary symptoms; COVID-19 as a syndrome has multisystemic involvement including frequent gastrointestinal symptoms such as diarrhea.
Creator
An entity primarily responsible for making the resource
Khanna, S., and C. S. Kraft.
Date
A point or period of time associated with an event in the lifecycle of the resource
2021-04-13
Type
The nature or genre of the resource
Publication
2019-nCoV
C-diff toxin
C. difficile toxin
Co-infection
Complications
Coronavirus
COVID-19
R-Res&Pub
-
https://repository.netecweb.org/files/original/468b071d8ab179d7b3c810106060e0d8.png
d032f43a51ea612bd01d2afda6c5ba92
https://repository.netecweb.org/files/original/8995c3a6b925ce1795c58e8d4b1328b9.pdf
4a37748cd456d101afe849aebbb32214
PDF Text
Text
NETEC Webinar Series
Influenza: 2022 Seasonal Update
�Content Outline (TOC)
Welcome
Trish Tennill, RN, BSN
�Overview
Welcome:
Trish Tennill, RN, BSN
Current U.S. Influenza Situation Report –
Trends and Management Considerations:
Influenza Vaccines 2022:
Gavin Harris, MD
Aileen Patel, MS, RN, CCRN
Influenza for the Frontline Provider:
Anna Yaffee, MD, MPH
Basic Infection Prevention & Control for Influenza:
Questions and Answers with NETEC
NETEC Resources:
Trish Tennill, RN, BSN
Trish Tennill, RN, BSN
Jill Morgan, RN, BSN
�NETEC Mission
NETEC sets and advances the gold standard for special
pathogen preparedness and response across health
care delivery systems with the goals of driving best
practices, closing knowledge gaps, and developing
innovative resources.
For more information
Please visit us at www.netec.org
or email us at info@netec.org
�Areas of Focus
Consultation
Education
Research Network
Deliver didactic and handson simulation training via
Build
Meet Fred
Empower hospitals to gauge
their readiness using
Self-Assessment
In-Person Courses
Measure facility and healthcare
worker readiness using
Central IRB Process
for rapid implementation of
clinical research protocols
Provide self-paced education through
Online Trainings
Metrics
Provide direct feedback to hospitals via
On-Site Assessment
Compile
Online Repository
Provide
of tools and resources
Develop Policies,
Procedures and Data
Capture Tools
to facilitate research
On-Site and Remote Guidance
Provide
Emergency On-Call
Mobilization
Develop customizable
Exercise Templates
based on the HSEEP model
Cross-Cutting, Supportive Activities
Create infrastructure for a
Specimen
Biorepository
�Content Outline (TOC)
Current U.S. Influenza SitRep:
Trends and Management
Considerations
Gavin Harris, MD
�Current U.S. Influenza Situation Report:
Trends and Management Considerations
A Weekly Influenza Surveillance Report Prepared by the Influenza Division
https://www.cdc.gov/flu/weekly/index.htm
Virologic surveillance – WHO and National Respiratory and Enteric Virus
Surveillance System; 100 public health and 300 clinical labs
Outpatient illness surveillance – Influenza-like Illness Surveillance
Network (ILINet) (approx. 3,000 outpatient providers)
Long-term Care Facilities
Hospitalization Surveillance – FluSurv-NET
Mortality Surveillance – National Center for Health Statistics Mortality
Surveillance Data
�Flu Activity Peak Months in the U.S.
1982-1983 Through 2021-2022 Flu Seasons
https://www.cdc.gov/flu/about/season/flu-season.htm
�Weekly Influenza Surveillance Report Prepared by the Influenza Division
2022-2023 Influenza Season Week 43 Ending October 29, 2022
https://www.cdc.gov/flu/weekly/index.htm
�Weekly Influenza Surveillance Report Prepared by the Influenza Division
Virologic Surveillance and Viral Characteristic Data for Week 43
https://www.cdc.gov/flu/weekly/index.htm
�Weekly Influenza Surveillance Report Prepared by the Influenza Division
Virologic Surveillance and Viral Characteristic Data for Week 43
https://www.cdc.gov/flu/weekly/index.htm
�Weekly Influenza Surveillance Report Prepared by the Influenza Division
Outpatient Respiratory Illness Visits Data for Week 43
By age group:
https://www.cdc.gov/flu/weekly/index.htm
�Weekly Influenza Surveillance Report Prepared by the Influenza Division
Hospitalization Surveillance Data for Week 43
https://www.cdc.gov/flu/weekly/index.htm
�The National Respiratory and Enteric Virus Surveillance System (NREVSS)
Respiratory Adenovirus National Trends
https://www.cdc.gov/surveillance/nrevss/adeno/natl-trend.html
�The National Respiratory and Enteric Virus Surveillance System (NREVSS)
RSV National Trends
https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html
�Current U.S. Influenza Situation Report:
Trends and Management Considerations
Epidemiology Summary
Regions 4 and 6 are reporting the highest levels of influenza activity
880,000 influenza illnesses, 6,900 hospitalizations, 360 deaths all
estimated from influenza thus far
Cumulative hospitalization rate in FluServ-NET system reported
higher in week 42 than every season since 2009
H3N2 is predominant strain; overwhelming burden thus far in older
people and younger children
Concomitant Respiratory Syncytial Virus and Adenovirus surge
�Current U.S. Influenza Situation Report:
Trends and Management Considerations
Predictors of Influenza in the U.S.
Northern and southern hemispheres have opposite respiratory
viral seasonality
• Australia had the worst influenza season in 5 years, cases 3
times higher than average; peaked two months earlier than
usual (May and June) and started in April
• Chile’s influenza positivity rates reached epidemic
thresholds in January, accompanied by an increase in
hospitalizations
Due to pandemic mitigation measures, low levels of circulating
influenza and decreased exposure = waning immunity over time
Australian Govt. Dept. of Health and Aged Car, accessed on 31 Oct 2022:
https://www1.health.gov.au/internet/main/publishing.nsf/Content/ozflu-surveil-no07-22.htm
CDC.gov, MMWR 28 October 2022
�Global Maps of the Estimated Average Epidemic Months
Respiratory syncytial virus (RSV)
Influenza A
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30264-5/fulltext
�Symptoms of Influenza
üFever*
üCough
üPharyngitis
üCoryza
üMyalgias/arthralgias
üHeadaches
üFatigue
üNausea/vomiting/diarrhea*
�Current U.S. Influenza Situation Report:
Trends and Management Considerations
Features of Influenza
Can be asymptomatic
Can experience symptoms 1-4 days after infection
• People are potentially contagious one day prior to symptoms
• Older children and adults most contagious 3-4 days after
infection but if immunocompromised may be even longer
Droplet and fomite spread most common
�Current U.S. Influenza Situation Report:
Trends and Management Considerations
Influenza Management Pillars
Antiviral treatment recommended as soon as possible for any
patient with suspected or confirmed influenza who:
• Is hospitalized
• Has severe, complicated, progressive illness
• Is at higher risk for severe illness
Initiation of antiviral treatment for patients with suspected
influenza should not wait for laboratory confirmation
• Ideally within 48hrs of illness onset
�Influenza Therapeutics
Neuraminidase inhibitors:
• Oseltamivir phosphate (PO)
• Zanamivir (Inh)
• Peramivir (IV)
Endonuclease inhibitor:
• Baloxavir marboxil (PO)
Adamantanes:
• Amantadine, rimantadine
�Coinfection Considerations
When to consider bacterial coinfection?
• Severe disease (extensive pneumonia, respiratory failure,
hypotension, fever)
• Deterioration after initial improvement
• Failure to improve after 3-5 days of antiviral therapy
Adjunctive therapy?
• Corticosteroids?
• Immunomodulation?
IDSA Practice Guidelines, 2018, Table 9
List of differential diagnoses to consider for patients
with influenza who do not improve or have clinical
deteriorations with antiviral treatment
https://www.idsociety.org/practice-guideline/influenza/
�Content Outline (TOC)
Influenza Vaccines 2022
Aileen Patel, MS, RN, CCRN
�Influenza Vaccines 2022
Influenza Vaccines: Who
CDC recommends vaccine for everyone 6 months or older
Specialized high dose formulation for those age 65 or older
• 3 options available for this age group
Higher risk groups include those who:
ü
ü
ü
ü
ü
ü
Are under age 2 and over age 50
Are residents of nursing homes and other long-term care facilities
Are pregnant or those planning to be pregnant during flu season
Have weakened immune systems
Have chronic illnesses
Have a body mass index (BMI) of 40 or higher
�Influenza Vaccines 2022
Influenza Vaccines: What
The influenza vaccine is available as an IM injection or as a nasal spray:
• Recommended by CDC for 2022-23 flu season
• Same formulation as for the Southern Hemisphere
(flu season April – October 2022)
• Composition recommendations available on CDC website
• Nasal spray vaccine is approved for those aged 2-49 years for those that opt
for this instead of IM route
Vaccine manufacturers have projected that they will supply the US with 173.5
to 183.5 million doses of influenza vaccine this season
• 2021-22 season: 175.6 million doses
• 2020-21 season: 194.4 million doses
https://www.cdc.gov/flu/season/faq-flu-season-2022-2023.htm#Flu-Vaccine
�Influenza Vaccines 2022
Influenza Vaccines: When
Most experts agree it is best to do before the end of October
• It takes approximately 2 weeks for immunity to develop after vaccination
Vaccination after October is still recommended to help protect in later months
• Flu typically peaks between December and February but can continue into May
Influenza and COVID vaccine coadministration
• You can get a COVID-19 vaccine/booster and a flu vaccine at the same time!
• Same advice for children
• People who received influenza vaccine + mRNA COVID-19 booster vaccine at the
same time were 8-11% more likely to report systemic reactions, including
fatigue, headache, and muscle ache
• Reactions mostly mild, resolved quickly
�Influenza Vaccines 2022
Influenza Vaccines: Where and Why
It is already circulating!
https://www.cdc.gov/flu/weekly/index.htm
�Influenza Vaccines 2022
Influenza Vaccines: Why
By some estimates, influenza causes more than
400,000 hospital stays and 50,000 deaths annually.
Influenza vaccine can lower the risk of getting
influenza and the risk of having serious illness
from influenza.
Last year's vaccine may not protect from this
year's viruses; new influenza vaccine
formulations are released annually to keep up
with rapidly changing influenza viruses,
Estimated Range of Annual Burden of Flu in the U.S.
from 2010 – 2020
https://www.cdc.gov/flu/about/burden/index.html
�Influenza Vaccines 2022
Influenza Vaccines: Why
Effectiveness of Seasonal Influenza Vaccines from the 2009-2021 Flu
Seasons:
https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm
�Content Outline (TOC)
Influenza for the Frontline Provider
Anna Yaffee, MD, MPH
�Influenza for the Frontline Provider
Overview
• Risk of respiratory virus surge, need to be prepared
• Follow the preparedness mantra of “Identify, Isolate”
• Take care of your patient, and your ED
• Prevention
�Influenza for the Frontline Provider
Identify
Identify through universal symptom (and travel) screen
First, any symptoms?
To Do:
Signs/Symptoms
Cough
Fever
Headache
Joint and muscl...
Weakness
Diarrhea
Vomiting
Abdominal pain
Rash
No symptoms
Second, any travel, and to where?
Travel:
Have you traveled outside in
the US in the past 21 days?
Yes
No
Link to countries
Ga. Department of Health Travel Link
�Influenza for the Frontline Provider
Why Universal?
Identify all hazards threats
• If not a special pathogen, patients may have other infectious
diseases like influenza, COVID-19 etc. which are important to
identify
Identification facilitates isolation
• Prevent waiting room/ED spread
• Prevent healthcare worker illness
�Influenza for the Frontline Provider
Isolate
�Isolate
Mask anyone with symptoms
Split triage flow
• Infectious vs Noninfectious
Move patients quickly to room
PPE and isolation precautions
Low Risk:
Referral to PCP or
COVID-19/Influenza Information Line
�Influenza for the Frontline Provider
Now What?
Next steps – clinical management!
• Supportive care
• Antivirals
• Testing for influenza and coinfections (COVID-19, expanded viral testing,
bacterial coinfection)
• Management of concomitant processes – cardiac, bacterial, sepsis
Prevention
• Influenza vaccine in ED
• Healthcare worker flu and COVID-19 vaccines
• Masking
�Influenza for the Frontline Provider
You are not alone!
Attention to frontline provider burnout, wellness
Foster fellowship within ED
Importance of advocacy at system level
�Content Outline (TOC)
Basic Infection Prevention &
Control for Influenza
Trish Tennill, RN, BSN
Jill Morgan, RN, BSN
�Basic Infection Prevention & Control for Influenza
Vaccinations
When
with
theFlu
Flu
Whendealing
dealing
with
Hand hygiene
The BEST
BEST defense
defense
is a
STRONG offense!
offense
STRONG
Appropriate PPE
Physical distancing
Self identification
�Respiratory Etiquette, Hand Hygiene, and Triage
Signage
Post signs or posters at each entrance and other
strategic places such as waiting areas, elevators,
restrooms, and cafeterias to provide patients
and visitors with instructions about respiratory
etiquette including:
• Using tissues to cover the nose and mouth
when coughing or sneezing
• Disposing of contaminated items in waste
receptacles
• Wearing a mask if symptomatic
• How and when to perform hand hygiene
�Respiratory Etiquette, Hand Hygiene, and Triage
Hand hygiene stations:
• Provide facemasks to patients with signs and
symptoms of respiratory infection.
• Provide supplies to perform hand hygiene to
all upon arrival to facility (e.g., at entrances,
waiting rooms, patient check-in) and
throughout the entire duration of the visit to
the healthcare setting.
�Respiratory Etiquette, Hand Hygiene, and Triage
Early Identification:
At the time of patient check-in or on arrival inquire about presence of
symptoms of a respiratory infection, and if present, provide instructions.
Early Isolation:
Provide space and encourage persons with symptoms of respiratory infections to sit
as far away from others as possible, place symptomatic patients in a separate waiting
area when possible. Consider engineering methods of infection control for
ventilation/filtration, administrative methods such as frequent cleaning, refilling
supplies, emptying trash.
During periods of high influenza activity in your community, consider
setting up triage or testing stations that allow the rapid screening of
patients for influenza and other respiratory pathogens before entry,
allowing them to remain separated from other patients.
Image from: https://dph.georgia.gov/covidtesting
�PPE for Influenza
Flu season is an opportunity to review usage and compliance and to
address habits that might contribute to the spread of infection.
• Hand hygiene after removing masks, respirators, or eye protection.
• Disposing of masks after use.
• Avoid touching eyes, nose, and mouth.
• Performing a user seal check each time a tight-fitting respirator
is worn.
Influenza PPE recommendations:
• Standard and Droplet precaution PPE ensembles vary by facility.
Surgical mask prior to influenza patient contact, gloves, with
some facilities adding gowns with or without eye protection.
• Aerosol generating procedures require respiratory and eye
protection
Healthcare facilities should be conducting fit testing. Remember
to perform a user-seal check every time a tight-fitting respirator
is put on.
Respect Yourself – Protect Yourself!
�Questions
and
Answers
�Content Outline (TOC)
Resources
�Resources
Resources related to influenza related topics:
• CDC - Frequently Asked Influenza Questions: https://www.cdc.gov/flu/season/faq-flu-season-2022-2023.htm
• CDC - Weekly U.S. Influenza Surveillance Report: https://www.cdc.gov/flu/weekly/index.htm
• CDC – Weekly U.S. Map – Influenza Summary Update: https://www.cdc.gov/flu/weekly/usmap.htm
• CDC – Disease Burden of Flu: https://www.cdc.gov/flu/about/burden/index.html
• CDC – Seasonal Flu Vaccine Effectiveness Studies: https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm
• Vaccines.gov - Find Flu Vaccine locator: https://www.vaccines.gov/find-vaccines/
• CDC - Consolidated Clinical Algorithm for Emergency Department Patients
with Acute Respiratory Illness Symptoms : https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians.htm
• CDC – Sequence for putting on PPE – Visual Guide PDF: https://www.cdc.gov/hai/pdfs/ppe/PPE-Sequence.pdf
�NETEC Resources
NETEC is Here to Help
NETEC will continue to build resources, develop online education,
and deliver technical training to meet the needs of our partners
Ask for help!
Send questions to info@netec.org - they will be answered by NETEC SMEs
Submit a Technical Assistance request at NETEC.org
�Contact
NETEC eLearning Center
NETEC Podcasts
NETEC Skill videos
courses.netec.org
“Transmission Interrupted”
youtube.com/thenetec
(On all major podcast players)
Join the Conversation!
@theNETEC
@the_NETEC
Use hashtag: #NETEC
Website
Resource Library
Email
netec.org
repository.netecweb.org
info@netec.org
��
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Develop
Description
An account of the resource
<h2><span>These files will help you <strong><em>develop</em></strong> your program and plans based on what you have discovered.</span></h2>
<p style="font-size:120%;">Find model protocols and procedures and more in-depth training resources. You can go to the <a href="/exhibits/show/leadership"><button>Leadership Toolbox</button></a> or the <a href="https://repository.netecweb.org/exhibits/show/specialpopulations"><button>Special Populations</button></a> section. You can also go to the <a href="https://repository.netecweb.org/exhibits/show/netec-education/justintime"><button> Just in Time Training</button></a> page, the <a href="https://repository.netecweb.org/exhibits/show/ppe101/ppe"><button> PPE</button></a> page, or the <a href="https://repository.netecweb.org/exhibits/show/ems/prehospital"><button>EMS</button></a> page. <span>Subscribe to the NETEC <a href="https://www.youtube.com/channel/UCDpHc1LkcEpiWR0q7ll5eZQ" target="_blank" rel="noreferrer noopener"><button>Youtube Channel</button></a> to get all new Skills videos!</span></p>
Webinar
Portal access to a webinar
Duration
Length of time involved (seconds, minutes, hours, days, class periods, etc.)
Nov 9, 2022 12:00 PM in Central Time (US and Canada)
Objectives
Discuss the current U.S. influenza data and the potential predictors for this year’s flu season.<br />Articulate what therapeutics are available for patients with influenza when addressing common symptoms and co-infections.<br />Describe infection prevention and control measures for detection, isolation, and management of influenza patients in emergency departments and other points of entry.
Event Type
Webinar, watch at link below.
URL
https://youtu.be/v0gXrxj4KNE
Player
Field for the html for a video player.
<br /><iframe width="560" height="315" src="https://www.youtube.com/embed/v0gXrxj4KNE?autoplay=0" title="YouTube video player" frameborder="0"></iframe>
Alternate URL
Other URLs if necessary.
CEU online Course: <a href="https://courses.netec.org/courses/influenza-2022-seasonal-update" target="_blank" title="Link to CEU course" rel="noreferrer noopener">https://courses.netec.org/courses/influenza-2022-seasonal-update</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
NETEC Webinar Series (11/09/22)/Online Course: Influenza: 2022 Seasonal Update
Subject
The topic of the resource
Emergency Management
Description
An account of the resource
This NETEC webinar will discuss the current landscape of influenza in the United States and the predictions for this year’s flu season. Additional topics will include available therapeutics to treat common symptoms and co-infections and infection prevention and control measures for the detection, isolation, and management of influenza patients this season.<br /><br />Webinar slides attached.<br /><br />
<h2 style="text-align:left;"><br />Get educational credit for this webinar through <a href="https://courses.netec.org/courses/influenza-2022-seasonal-update" target="_blank" title="CEU link" rel="noreferrer noopener">Courses.netec.org</a>.</h2>
Creator
An entity primarily responsible for making the resource
NETEC
Date
A point or period of time associated with an event in the lifecycle of the resource
2022-11-09
Coverage
The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant
2023-12-19
Contributor
An entity responsible for making contributions to the resource
From Benjamin: Release Date: 12/20/2022; Expires: 12/19/2023
Type
The nature or genre of the resource
Webinar and Online Course
Co-infection
Influenza
Online Course
R-EM
Therapeutics
Webinar